PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo: Net Profits Down 85% Due to Allowance for Potential Losses Related to Quality Problems Caused by Ranbaxy
May 15, 2012
- Otsuka HD: Pharma Sales, Profits Up; Sales of Abilify Break 400 Billion
May 15, 2012
- Eisai’s US Subsidiary Expands Exclusive Marketing Rights for Anti-Obesity Agent to 20 Countries in Americas
May 14, 2012
- Sales of Lipitor Down 6% in Fiscal Year Ended March 2012: Astellas
May 14, 2012
- Sales Force Effectiveness Japan 2012 to Be Held on July 10, 11
May 14, 2012
- Sales Up 1.6%, Vesicare Extends Global Growth: Astellas
May 14, 2012
- DSP’s Sales, Profits Down Due to Strong Yen, 1.6% Decline in Domestic Business
May 14, 2012
- DSP to Reconstruct its Business Strategy Due to Acquisition of BBI and Slow Business in North America
May 14, 2012
- The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
- Struggles in US Operations Lead to 5.3% Fall in Sales, Strategic Products at Home Post 25% Rise: Shionogi
May 11, 2012
- “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
- Seikagaku Licenses Domestic Marketing Rights to Kaken Pharmaceutical for Hernia Treatment SI-6603
May 11, 2012
- Executive Officer Terukazu Kato to Become New President: Tsumura
May 11, 2012
- Ono Aims to Decrease Sales Ratio of Long-Listed Drugs to 50% Level within FY2012: President Sagara
May 11, 2012
- Senior Executive Director Mitsutomo Miyashita to Be Appointed as New President: Kyorin
May 11, 2012
- Company Results for March Show Slight Fall in Drug Sales on Impact of Generics: MTPC
May 10, 2012
- Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
- Japan Blood Products Organization to Begin Operations in October: JRCS, MTPC
May 10, 2012
- Once-Monthly Abilify Significantly Extends Time to Relapse in Adult Schizophrenia Patients: Otsuka
May 10, 2012
- Shionogi’s US Subsidiary Submits NDA for VVA Treatment Ospemifene in the US
May 10, 2012
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…